Rapport Therapeutics (RAPP) Shares Outstanding (Weighted Average) (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Shares Outstanding (Weighted Average) data on file, last reported at $47.2 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $47.2 million, up 33.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.2 million (up 33.94% YoY), and the FY2025 annual result was $38.9 million, up 87.74% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $47.2 million in Q1 2026 per RAPP's latest filing, from $38.9 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $47.2 million in Q1 2026 and troughed at $1.4 million in Q2 2023.
• A 4-year average of $21.8 million and a median of $27.8 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) surged 2312.73% in 2024, then advanced 3.92% in 2025.
• A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $1.5 million in 2023, then surged by 1277.25% to $20.7 million in 2024, then jumped by 87.74% to $38.9 million in 2025, then gained by 21.32% to $47.2 million in 2026.
• Business Quant data shows RAPP's Shares Outstanding (Weighted Average) at $47.2 million in Q1 2026, $38.9 million in Q4 2025, and $36.2 million in Q3 2025.